GEFITINIB and RASH

Overview

RASH is the #5 most commonly reported adverse reaction for GEFITINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 638 FDA adverse event reports linking GEFITINIB to RASH. This represents approximately 3.7% of all 17,300 adverse event reports for this drug.

Patients taking GEFITINIB who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

RASH is moderately reported among GEFITINIB users, representing a notable but not dominant share of adverse events.

Other Side Effects of GEFITINIB

In addition to rash, the following adverse reactions have been reported for GEFITINIB:

• MALIGNANT NEOPLASM PROGRESSION — 1,811 reports
• DRUG RESISTANCE — 1,246 reports
• DIARRHOEA — 900 reports
• DEATH — 753 reports
• DISEASE PROGRESSION — 456 reports
• INTERSTITIAL LUNG DISEASE — 419 reports
• NAUSEA — 376 reports
• METASTASES TO CENTRAL NERVOUS SYSTEM — 373 reports
• DYSPNOEA — 331 reports
• VOMITING — 325 reports

Other Drugs Associated with RASH

The following drugs have also been linked to rash in FDA adverse event reports:

Does GEFITINIB cause RASH?

RASH has been reported as an adverse event in 638 FDA reports for GEFITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is RASH with GEFITINIB?

RASH accounts for approximately 3.7% of all adverse event reports for GEFITINIB, making it a notable side effect.

What should I do if I experience RASH while taking GEFITINIB?

If you experience rash while taking GEFITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages